Finance

Lists
CSPCY:OTCMKTS
CSPC Pharmaceuticals Group ADR
5,00 US$
-1,96%
(-0,100) 1D
5 ოქტ, 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CSPCY...
Open
4,96 US$
High
5,00 US$
Low
4,96 US$
Mkt. cap
113,55 მლრ.
Avg. vol.
1,40 ათ.
Volume
545,00
52-wk high
5,46 US$
52-wk low
3,26 US$
Beta
0,37
Shares outstanding
2,88 მლრდ.
No. of employees
19 ათ.
Open
4,96 US$
High
5,00 US$
Low
4,96 US$
Mkt. cap
113,55 მლრ.
Avg. vol.
1,40 ათ.
Volume
545,00
52-wk high
5,46 US$
52-wk low
3,26 US$
Beta
0,37
Shares outstanding
2,88 მლრდ.
No. of employees
19 ათ.
News stories
From web sources and news partners
TipRanks
TipRanks
·
11 საათის წინ
CSPC to Showcase Breakthrough HER2 Oncology Data at ESMO 2026
Profile
CSPC Pharmaceutical Group researches, develops, manufactures and sells pharmaceutical products. Its headquarters is in China's Hebei Province. CSPC produces both active pharmaceutical ingredient and formulations. API products include penicillin, cefalosporins, synthetic vitamins, caffeine and ranitidine. Formulations include antibiotics, butylphthalide and analgesics, in addition to nearly 1,000 other products. CSPC's 15,000 employees are divided among more than ten subsidiaries, including CSPC Zhongrun, Weisheng, Zhongnuo and NBP. CSPC Pharma's total assets are valued above RMB 8 billion. In 2007, CSPC Pharma achieved sales of RMB 8 billion and net income of RMB 485 million. Direct exports of US$300 million ranked CSPC first among China's pharmaceutical enterprises. One subsidiary, China Pharmaceutical Group Co., Ltd is based in Hong Kong. It is listed on the Hang Seng China-Affiliated Corporations Index. In 2003 and 2004, China Pharma was listed as one of 100 excellent listed companies with turnover less than $1 billion. CSPC Pharma is recognized as one of China's "500 Most Valuable Chinese Brands" and "Top 500 Chinese Enterprises." Wikipedia
About CSPC Pharmaceuticals Group ADR
CEOZhang Cuilong
Employees18,6 ათ.
Founded1992
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in HKD
Loading Previous Earnings...
Revenue
Net income
All values in CNY
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
6,62 მლრდ.
6,11 მლრდ.
6,47 მლრდ.
12,13 მლრდ.
Cost of goods sold
2,28 მლრდ.
2,11 მლრდ.
2,20 მლრდ.
2,24 მლრდ.
Cost of revenue
2,28 მლრდ.
2,11 მლრდ.
2,20 მლრდ.
2,24 მლრდ.
Research and development expenses
1,50 მლრდ.
1,62 მლრდ.
1,40 მლრდ.
1,63 მლრდ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,97 მლრდ.
1,87 მლრდ.
1,89 მლრდ.
1,89 მლრდ.
Operating expense
3,47 მლრდ.
3,49 მლრდ.
3,29 მლრდ.
3,51 მლრდ.
Total operating expenses
5,75 მლრდ.
5,60 მლრდ.
5,49 მლრდ.
5,75 მლრდ.
Operating income
869,63 მლნ.
514,71 მლნ.
973,82 მლნ.
6,38 მლრდ.
Other non operating income
645,14 მლნ.
-470,42 მლნ.
181,80 მლნ.
11,92 მლნ.
EBT including unusual items
1,18 მლრდ.
505,59 მლნ.
1,13 მლრდ.
6,40 მლრდ.
EBT excluding unusual items
1,37 მლრდ.
186,56 მლნ.
1,13 მლრდ.
6,35 მლრდ.
Income tax expense
222,47 მლნ.
165,64 მლნ.
243,25 მლნ.
825,70 მლნ.
Effective tax rate
18,78%
32,76%
21,46%
12,91%
Other operating expenses
-
-
-
-
Net income
963,54 მლნ.
370,72 მლნ.
859,79 მლნ.
5,23 მლრდ.
Net profit margin
14,56%
6,06%
13,30%
43,16%
Earnings per share
-
-
-
-
Interest and investment income
-
195,87 მლნ.
-
91,68 მლნ.
Interest expense
-104,94 მლნ.
-6,76 მლნ.
-11,01 მლნ.
-2,30 მლნ.
Net interest expenses
-104,94 მლნ.
189,12 მლნ.
-11,01 მლნ.
89,37 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
1,14 მლრდ.
802,06 მლნ.
1,26 მლრდ.
6,67 მლრდ.
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google აპები